Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cocrystal Pharma Inc COCP

Healthcare
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function... see more

Recent & Breaking News (NDAQ:COCP)

Cocrystal Pharma Presents Positive Data from U.S. Phase 2a Study of CC-31244 Demonstrating Ability to Identify Patients More Likely to Respond to Ultrashort Treatment of HCV

GlobeNewswire November 11, 2019

COCRYSTAL PHARMA, INC. PRICES $3,000,000 UNDERWRITTEN PUBLIC OFFERING

GlobeNewswire October 31, 2019

COCRYSTAL PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

GlobeNewswire October 30, 2019

Cocrystal Pharma Announces New Data on CC-31244 and Abstract Acceptance for Poster Presentation at the AASLD 2019 Liver Meeting

GlobeNewswire October 30, 2019

Cocrystal Pharma Presents Data at the 26th International Symposium on Hepatitis C Virus and Related Viruses

GlobeNewswire October 8, 2019

Cocrystal Pharma Announces Abstract Accepted for Poster Presentation at 26th International Symposium on Hepatitis C Virus and Related Viruses

GlobeNewswire October 1, 2019

Cocrystal Pharma to Present at the 2019 Cantor Global Healthcare Conference

GlobeNewswire September 26, 2019

Cocrystal Pharma Presents Positive Preclinical Data for CC-42344 at the Options X for the Control of Influenza Conference

GlobeNewswire September 3, 2019

Cocrystal Pharma Announces Abstract Accepted for Oral Presentation at the ISIRV: Options X for the Control of Influenza Conference

GlobeNewswire August 21, 2019

Cocrystal Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire August 9, 2019

Cocrystal Pharma Commences Patient Enrollment for Hong Kong Phase 2a Study of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus

GlobeNewswire May 20, 2019

Cocrystal Pharma Reports First Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire May 10, 2019

Cocrystal Pharma Reports 2018 Financial Results and Provides Corporate Overview and Business Outlook

GlobeNewswire April 1, 2019

Cocrystal Pharma Announces Closing of Private Placement

GlobeNewswire March 11, 2019

Cocrystal Pharma Provides Update on Clinical Development Program Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C Virus

GlobeNewswire January 22, 2019

Robbins Arroyo LLP: Shareholder Lawsuit Says Cocrystal Pharma, Inc. (COCP) Misled Shareholders

Business Wire January 18, 2019

Cocrystal Announces Board Changes

GlobeNewswire January 7, 2019

Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck

GlobeNewswire January 3, 2019

Cocrystal Pharma Announces Presentation at the RespiDART 2018: Frontiers in Drug Development Against Respiratory Viruses Conference

GlobeNewswire November 30, 2018

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cocrystal Pharma, Inc. (Formerly BioZone Pharmaceuticals, Inc.) and Encourages Investors with Losses of $100,000 to Contact the Firm

Business Wire November 19, 2018